Cargando…

2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study

BACKGROUND: Ceftaroline (CPT) is a last generation cephalosporin with activity against MRSA. Recent data raised concerns regarding routine susceptibility testing in clinical laboratories, suggesting a poor performance for detecting nonsusceptible S. aureus (MIC >1 µg/dL) using either disc or grad...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivas, Lina M, Spencer, Maria, Zumaran, Cecilia, Lam, Marusella, Silva, Francisco, Cifuentes, Marcela, Rojas, Pamela, Braun, Stephanie, Valdivieso, Francisca, Mühlhauser, Margareta, Lafourcade, Mónica, Fuenzalida, Luz, Moreno, Victoria, Porte, Lorena, Araos, Rafael, Garcia, Patricia, Munita, Jose M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253235/
http://dx.doi.org/10.1093/ofid/ofy210.1715
_version_ 1783373451149443072
author Rivas, Lina M
Spencer, Maria
Zumaran, Cecilia
Lam, Marusella
Silva, Francisco
Cifuentes, Marcela
Rojas, Pamela
Braun, Stephanie
Valdivieso, Francisca
Mühlhauser, Margareta
Lafourcade, Mónica
Fuenzalida, Luz
Moreno, Victoria
Porte, Lorena
Araos, Rafael
Garcia, Patricia
Munita, Jose M
author_facet Rivas, Lina M
Spencer, Maria
Zumaran, Cecilia
Lam, Marusella
Silva, Francisco
Cifuentes, Marcela
Rojas, Pamela
Braun, Stephanie
Valdivieso, Francisca
Mühlhauser, Margareta
Lafourcade, Mónica
Fuenzalida, Luz
Moreno, Victoria
Porte, Lorena
Araos, Rafael
Garcia, Patricia
Munita, Jose M
author_sort Rivas, Lina M
collection PubMed
description BACKGROUND: Ceftaroline (CPT) is a last generation cephalosporin with activity against MRSA. Recent data raised concerns regarding routine susceptibility testing in clinical laboratories, suggesting a poor performance for detecting nonsusceptible S. aureus (MIC >1 µg/dL) using either disc or gradient strips (Cantón R 2017) AIM: To evaluate the results of CPT susceptibility testing with Etest(®) and disk diffusion (Kirby–Bauer technique [KB]) as compared with broth microdilution (BMD), in clinical isolates of MRSA obtained from different hospitals in Santiago, Chile. METHODS: During 2017, we prospectively collected consecutive clinical strains of MRSA recovered from the blood or other sterile sites in ten tertiary-care hospitals in Santiago, Chile. One isolate per patient was obtained. Identification was confirmed by MALDI-TOF and susceptibility testing of all isolates was performed at a central lab. CPT susceptibility was evaluated by BMD and KB following CLSI 2017 directions. Etest was performed as per manufacturer’s instructions. Categorical agreement (CA), essential agreement (EA) and very major errors (VME) were evaluated. Susceptibilities were analyzed using CLSI established breakpoints RESULTS: Forty unique MRSA isolates were tested. Using BMD, the MIC(50)/MIC(90) was 2/4 μg/dL, respectively. Moreover, only 18 (45%) isolates were CPT susceptible. Out of the remaining 22 MRSA strains, 8 (20%) were intermediate and 14 (35%) CPT-resistant (CPT-R). Using Etest, the MIC(50)/MIC(90) was 1/2 μg/dL, with 31 (78%) isolates being considered susceptible and the remaining catalogued as intermediate. CPT susceptibility using KB catalogued 38 (95%) isolates as susceptible and only 2 as intermediate. No CPT-R strains were found by Etest or KB. The CA was for Etest and KB, respectively; Etest’s EA was 80%. Worryingly, out of 14 CPT-R isolates by BMD, 6 were deemed susceptible by Etest and 12 by KB, obtaining VME rates of 43 and 87%, respectively CONCLUSION: Performance of both Etest and KB to assess CPT susceptibility in MRSA isolates from Chile was poor, with a unacceptably high proportion of VME, and a CA lower than 50% for both techniques. Correlation of CPT susceptibility with the molecular epidemiology of the isolates is currently being performed DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253235
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62532352018-11-28 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study Rivas, Lina M Spencer, Maria Zumaran, Cecilia Lam, Marusella Silva, Francisco Cifuentes, Marcela Rojas, Pamela Braun, Stephanie Valdivieso, Francisca Mühlhauser, Margareta Lafourcade, Mónica Fuenzalida, Luz Moreno, Victoria Porte, Lorena Araos, Rafael Garcia, Patricia Munita, Jose M Open Forum Infect Dis Abstracts BACKGROUND: Ceftaroline (CPT) is a last generation cephalosporin with activity against MRSA. Recent data raised concerns regarding routine susceptibility testing in clinical laboratories, suggesting a poor performance for detecting nonsusceptible S. aureus (MIC >1 µg/dL) using either disc or gradient strips (Cantón R 2017) AIM: To evaluate the results of CPT susceptibility testing with Etest(®) and disk diffusion (Kirby–Bauer technique [KB]) as compared with broth microdilution (BMD), in clinical isolates of MRSA obtained from different hospitals in Santiago, Chile. METHODS: During 2017, we prospectively collected consecutive clinical strains of MRSA recovered from the blood or other sterile sites in ten tertiary-care hospitals in Santiago, Chile. One isolate per patient was obtained. Identification was confirmed by MALDI-TOF and susceptibility testing of all isolates was performed at a central lab. CPT susceptibility was evaluated by BMD and KB following CLSI 2017 directions. Etest was performed as per manufacturer’s instructions. Categorical agreement (CA), essential agreement (EA) and very major errors (VME) were evaluated. Susceptibilities were analyzed using CLSI established breakpoints RESULTS: Forty unique MRSA isolates were tested. Using BMD, the MIC(50)/MIC(90) was 2/4 μg/dL, respectively. Moreover, only 18 (45%) isolates were CPT susceptible. Out of the remaining 22 MRSA strains, 8 (20%) were intermediate and 14 (35%) CPT-resistant (CPT-R). Using Etest, the MIC(50)/MIC(90) was 1/2 μg/dL, with 31 (78%) isolates being considered susceptible and the remaining catalogued as intermediate. CPT susceptibility using KB catalogued 38 (95%) isolates as susceptible and only 2 as intermediate. No CPT-R strains were found by Etest or KB. The CA was for Etest and KB, respectively; Etest’s EA was 80%. Worryingly, out of 14 CPT-R isolates by BMD, 6 were deemed susceptible by Etest and 12 by KB, obtaining VME rates of 43 and 87%, respectively CONCLUSION: Performance of both Etest and KB to assess CPT susceptibility in MRSA isolates from Chile was poor, with a unacceptably high proportion of VME, and a CA lower than 50% for both techniques. Correlation of CPT susceptibility with the molecular epidemiology of the isolates is currently being performed DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253235/ http://dx.doi.org/10.1093/ofid/ofy210.1715 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Rivas, Lina M
Spencer, Maria
Zumaran, Cecilia
Lam, Marusella
Silva, Francisco
Cifuentes, Marcela
Rojas, Pamela
Braun, Stephanie
Valdivieso, Francisca
Mühlhauser, Margareta
Lafourcade, Mónica
Fuenzalida, Luz
Moreno, Victoria
Porte, Lorena
Araos, Rafael
Garcia, Patricia
Munita, Jose M
2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title_full 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title_fullStr 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title_full_unstemmed 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title_short 2059. Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study
title_sort 2059. comparative evaluation of ceftaroline susceptibility methods in clinical isolates of methicillin-resistant staphylococcus aureus (mrsa): results from a multicenter study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253235/
http://dx.doi.org/10.1093/ofid/ofy210.1715
work_keys_str_mv AT rivaslinam 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT spencermaria 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT zumarancecilia 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT lammarusella 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT silvafrancisco 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT cifuentesmarcela 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT rojaspamela 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT braunstephanie 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT valdiviesofrancisca 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT muhlhausermargareta 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT lafourcademonica 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT fuenzalidaluz 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT morenovictoria 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT portelorena 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT araosrafael 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT garciapatricia 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy
AT munitajosem 2059comparativeevaluationofceftarolinesusceptibilitymethodsinclinicalisolatesofmethicillinresistantstaphylococcusaureusmrsaresultsfromamulticenterstudy